A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Trial Profile

A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Larotrectinib (Primary) ; Larotrectinib (Primary)
  • Indications CNS cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SCOUT
  • Sponsors Loxo Oncology
  • Most Recent Events

    • 20 Dec 2017 According to a Loxo Oncology media release, the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed following prior treatment or who have no acceptable alternative treatments.
    • 04 Dec 2017 Brian Turpin is the principal investigator of this trial, according to a Loxo Oncology media release.
    • 04 Dec 2017 According to a Loxo Oncology media release, results from this trial were presented at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top